Hematopoietic stem cell engineering at a crossroads.
暂无分享,去创建一个
[1] Yang Xu,et al. Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. , 2010, Cell stem cell.
[2] D. Persons. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in β‐thalassemia patients , 2010, Annals of the New York Academy of Sciences.
[3] T. Enver,et al. Forcing cells to change lineages , 2009, Nature.
[4] Hojun Li,et al. In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.
[5] Alexander Meissner,et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.
[6] Kathryn L. Parsley,et al. Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency , 2011, Science Translational Medicine.
[7] R. Mulligan,et al. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[8] C. D. de Graaf,et al. The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal , 2010, Science.
[9] F. Gage,et al. In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.
[10] P. Kantoff,et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[11] A. Fischer,et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. , 1990, The New England journal of medicine.
[12] Bruce Aronow,et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.
[13] F. Bushman,et al. Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.
[14] A. Rimek,et al. High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation. , 2003, Blood.
[15] Dana Carroll,et al. Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.
[16] M. Blasco,et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.
[17] M. Sadelain,et al. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] A. Miller,et al. Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.
[19] H. Kiem,et al. Efficient transduction and engraftment of G-CSF-mobilized peripheral blood CD34+ cells in nonhuman primates using GALV-pseudotyped gammaretroviral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] C. von Kalle,et al. Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] H. Heslop,et al. An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.
[22] C. von Kalle,et al. Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] T. Enver,et al. Impaired embryonic haematopoiesis yet normal arterial development in the absence of the Notch ligand Jagged1 , 2008, The EMBO journal.
[24] E. Medico,et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. , 2005, Blood.
[25] Shinya Yamanaka,et al. Immunogenicity of induced pluripotent stem cells. , 2011, Circulation research.
[26] A. Schambach,et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[27] Donald B Kohn,et al. Update on gene therapy for immunodeficiencies. , 2010, Clinical immunology.
[28] M. Mcclure,et al. Progress and prospects: Foamy virus vectors enter a new age , 2010, Gene Therapy.
[29] D. Heim,et al. Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency , 2000, Immunological reviews.
[30] Shoshannah L. Roth,et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy , 2011, Nucleic acids research.
[31] Shin-Ichi Nishikawa,et al. Continuous single-cell imaging of blood generation from haemogenic endothelium , 2009, Nature.
[32] Michel Sadelain,et al. Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.
[33] P. Glazer,et al. Triplex forming oligonucleotides: sequence-specific tools for gene targeting. , 2001, Human molecular genetics.
[34] Daniel G. Miller,et al. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] E. Kirkness,et al. Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.
[36] E. Bouhassira,et al. Gene Specificity of Suppression of Transgene-Mediated Insertional Transcriptional Activation by the Chicken HS4 Insulator , 2009, PloS one.
[37] A. Nienhuis,et al. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. , 2008, Blood.
[38] Russell J. Taylor,et al. Bioluminescent Imaging Demonstrates That Transplanted Human Embryonic Stem Cell‐Derived CD34+ Cells Preferentially Develop into Endothelial Cells , 2009, Stem cells.
[39] D. Clapp,et al. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. , 1998, Blood.
[40] R. Nagel,et al. Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy , 2001, Science.
[41] P. Glazer,et al. Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[42] Sridhar Hannenhalli,et al. Genome-wide analysis of retroviral DNA integration , 2005, Nature Reviews Microbiology.
[43] Michel Sadelain,et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin , 2000, Nature.
[44] Frédéric Pâques,et al. Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. , 2007, Current gene therapy.
[45] B. Palmer,et al. Safety and Efficacy of a Lentiviral Vector Containing Three Anti-HIV Genes-CCR5 Ribozyme, Tat-rev siRNA, and TAR Decoy-in SCID-hu Mouse-Derived T Cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[46] T. Ichisaka,et al. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.
[47] S. Orkin,et al. The emergence of hematopoietic stem cells is initiated in the placental vasculature in the absence of circulation. , 2008, Cell stem cell.
[48] M. Sadelain. Eliminating cells gone astray. , 2011, The New England journal of medicine.
[49] David A. Williams,et al. Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia. , 2009, Mutation research.
[50] D. Kohn,et al. Gene therapy fulfilling its promise. , 2009, The New England journal of medicine.
[51] M. Sadelain,et al. Stem cell engineering for the treatment of severe hemoglobinopathies. , 2008, Current molecular medicine.
[52] Yoav Mayshar,et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. , 2010, Cell stem cell.
[53] Bin Zhang,et al. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. , 2008, The Journal of clinical investigation.
[54] Riitta Lahesmaa,et al. Copy number variation and selection during reprogramming to pluripotency , 2011, Nature.
[55] C. Dunbar,et al. Contributions of gene marking to cell and gene therapies. , 2011, Human gene therapy.
[56] G. Gahrton,et al. TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy. , 2010, Human gene therapy.
[57] B. Wood,et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. , 2008, The Journal of clinical investigation.
[58] K. Ikeda,et al. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. , 2011, Blood.
[59] C. von Kalle,et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. , 2005, Blood.
[60] Irving L. Weissman,et al. Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding , 2011, Nature Biotechnology.
[61] T. Wolfsberg,et al. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[62] John J Rossi,et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[63] K. Kissa,et al. Blood stem cells emerge from aortic endothelium by a novel type of cell transition , 2010, Nature.
[64] Julie V. Harness,et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. , 2011, Cell stem cell.
[65] S. Yamanaka. Strategies and new developments in the generation of patient-specific pluripotent stem cells. , 2007, Cell stem cell.
[66] C. von Kalle,et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. , 2006, Blood.
[67] F. Bushman,et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.
[68] K. Sugamura,et al. gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. , 1996, Blood.
[69] B. Aronow,et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates , 2003, Nature Medicine.
[70] A. Consiglio,et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells , 2009, Nature.
[71] Hans Martin,et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.
[72] D. Russell,et al. Transduction of hematopoietic cells by foamy virus vectors. , 1996, Blood.
[73] T. Shimada,et al. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[74] P. Andrews,et al. Culture and characterization of human embryonic stem cells. , 2004, Stem cells and development.
[75] Christof von Kalle,et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.
[76] G. Daley,et al. Correction of a Genetic Defect by Nuclear Transplantation and Combined Cell and Gene Therapy , 2002, Cell.
[77] Shawn M. Burgess,et al. Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.
[78] Hans-Peter Kiem,et al. Foamy virus vector integration sites in normal human cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[79] Jean A. Roayaei,et al. Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. , 2009, Blood.
[80] N. Copeland,et al. Insertional Mutagenesis Identifies Genes That Promote the Immortalization/Self-Renewal of Primary Bone Marrow Progenitor Cells. , 2005 .
[81] Luca Biasco,et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.
[82] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[83] C. Baum,et al. The genomic risk of somatic gene therapy. , 2010, Seminars in cancer biology.
[84] A. Schnerch,et al. Direct conversion of human fibroblasts to multilineage blood progenitors , 2010, Nature.
[85] David R. Liu,et al. Revealing Off-Target Cleavage Specificities of Zinc Finger Nucleases by In Vitro Selection , 2011, Nature Methods.
[86] D. Kohn. Gene therapy for genetic haematological disorders and immunodeficiencies , 2001, Journal of internal medicine.
[87] C. Dunbar,et al. Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. , 2001, The Journal of clinical investigation.
[88] C. L. Li,et al. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[89] Manuel Serrano,et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.
[90] A. Nienhuis,et al. Genotoxicity of retroviral integration in hematopoietic cells. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[91] M. Stojkovic,et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. , 2008, Cell stem cell.
[92] Jérôme Larghero,et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.
[93] Christine Kinnon,et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. , 2007, The Journal of clinical investigation.
[94] A. Ciuffi. Mechanisms governing lentivirus integration site selection. , 2008, Current gene therapy.
[95] Paul Shinn,et al. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.
[96] Michel Sadelain,et al. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells , 2011, Nature Biotechnology.
[97] Adrian P Gee,et al. Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.
[98] K. van Besien,et al. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[99] Prashant Mali,et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. , 2009, Cell stem cell.
[100] P. Malik,et al. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[101] Christof von Kalle,et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. , 2010, The New England journal of medicine.
[102] A. Thrasher,et al. Progress and prospects: gene therapy for inherited immunodeficiencies , 2009, Gene Therapy.
[103] Kathryn L. Parsley,et al. Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.
[104] K. Schwarz,et al. Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[105] Marius Wernig,et al. Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.
[106] Jeffrey C. Miller,et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity , 2011, Nature Biotechnology.
[107] Vanessa Taupin,et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.
[108] S. Rivella,et al. Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. , 1998, Seminars in hematology.
[109] D. W. Emery. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. , 2011, Human gene therapy.
[110] Cameron S. Osborne,et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.
[111] Christine Kinnon,et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.
[112] Michael S. Becker,et al. Fate tracing reveals the endothelial origin of hematopoietic stem cells. , 2008, Cell stem cell.
[113] Brian E. McIntosh,et al. Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy , 2011, Proceedings of the National Academy of Sciences.
[114] P. Gregory,et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.
[115] Jens Boch,et al. TALEs of genome targeting , 2011, Nature Biotechnology.
[116] Christof von Kalle,et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.
[117] Yang Du,et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.
[118] Christof von Kalle,et al. Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells , 2004, PLoS biology.
[119] Keiichiro Suzuki,et al. Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors , 2008, Proceedings of the National Academy of Sciences.
[120] Christian Schuetz,et al. Regeneration and orthotopic transplantation of a bioartificial lung , 2010, Nature Medicine.
[121] L. Zon,et al. Hematopoiesis: An Evolving Paradigm for Stem Cell Biology , 2008, Cell.
[122] P. Andrews,et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo , 2007, Nature Biotechnology.
[123] J. Dick,et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression , 2005, The Journal of experimental medicine.
[124] W. Ostertag,et al. FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells , 1998, Gene Therapy.
[125] N. Galjart,et al. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium , 2010, Nature.
[126] C. Dunbar,et al. Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. , 1996, Annual review of medicine.
[127] Gianluigi Zanetti,et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. , 2011, Blood.
[128] Christine Kinnon,et al. Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.
[129] B. Fehse,et al. Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking , 2005, Science.
[130] T. Bestor. Gene silencing as a threat to the success of gene therapy. , 2000, The Journal of clinical investigation.
[131] R. Ghirlando,et al. Chromatin boundaries, insulators, and long-range interactions in the nucleus. , 2010, Cold Spring Harbor symposia on quantitative biology.
[132] Christof von Kalle,et al. and insertional genotoxicity Cell culture assays reveal the importance of retroviral vector design for , 2006 .
[133] Luigi Naldini,et al. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications , 2009, Nature Reviews Genetics.
[134] James M. Allen,et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors , 2008, Nature Medicine.
[135] J. Ellis. Silencing and variegation of gammaretrovirus and lentivirus vectors. , 2005, Human gene therapy.
[136] S. Rivella,et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. , 2000, Nature.
[137] R. Nagel,et al. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[138] Anitha Rao,et al. RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.
[139] Manfred Schmidt,et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.
[140] C. von Kalle,et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. , 2005, Blood.
[141] Angelique M. Nelson,et al. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[142] Michel Sadelain,et al. Occurrence of leukaemia following gene therapy of X-linked SCID , 2003, Nature Reviews Cancer.
[143] J. Ihle,et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients , 1993, The Lancet.
[144] R. Humphries,et al. Effects of HOXB4 Overexpression on Ex Vivo Expansion and Immortalization of Hematopoietic Cells from Different Species , 2007, Stem cells.
[145] M. Jasin,et al. Genetic manipulation of genomes with rare-cutting endonucleases. , 1996, Trends in genetics : TIG.